On June 15, Innovent Biologics rose 3.01% in regular trading, trading at HKD 78.7/share, with turnover of HKD 363 million. The stock rebounded after consecutive sessions of decline, driven by dual catalysts of a new product approval and academic conference data.

The company recently received approval for its first domestic PCSK9 inhibitor injection, making it the tenth commercialized product in its portfolio and further strengthening its cardiovascular-metabolic pipeline. Additionally, mazdutide data presented at the 86th ADA Scientific Sessions — including three oral presentations covering severe obesity, type 2 diabetes with obesity, and adolescent obesity populations — provided further positive momentum.

The stock had previously pulled back from its May 29 peak gain of over 11% following the announcement of a USD 10.5 billion global strategic collaboration with Pfizer, as markets questioned regulatory approval certainty. Today's rebound was supported by broader biotech sector strength, with 3SBio rising 4.65% and Akeso gaining 1.14%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)